TNF-α has been shown to play a critical role in the pathogenesis of IBD and biological therapy with TNF-α-blockers has been used as a mainstream treatment for downregulating aberrant immune responses and inflammatory cascades [42]. Here, TNF is linked to inflammatory bowel disease.